Ocugen, Inc. 8-K

What Happened

• On July 13, 2026, Ocugen, Inc. (OCGN) filed a Form 8-K reporting that it signed a binding term sheet to license OCU400, its modifier gene therapy for retinitis pigmentosa, for the Middle East and North Africa (MENA) region. The company issued a press release the same day (attached as Exhibit 99.1 to the filing).

Key Details

• Date of filing and announcement: July 13, 2026.
• Program: OCU400 modifier gene therapy for retinitis pigmentosa.
• Territory covered: Middle East and North Africa (MENA).
• Disclosure: The 8-K references a binding term sheet and includes a press release; the filing does not disclose financial terms or payment/royalty details.

Why It Matters

• This transaction signals Ocugen's business-development progress for OCU400 and expansion of potential geographic reach into the MENA region.
• Because the 8-K does not include commercial or financial terms, the immediate financial impact is unclear; investors should watch for future filings (e.g., a definitive license agreement) that provide material terms and potential revenue implications.